Loading...
Explore Symbiotec Pharmalab IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Company Overview: Symbiotec Pharmalab Ltd.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company specializing in the research-driven development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves the pharmaceutical, nutraceutical, and wellness industries across both domestic and international markets.
Key Highlights:
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 24 Aug - 27 Aug 2026 |
| IPO Price Band | ₹938 - ₹988 per share |
| Fresh Issue | ₹150.00 crore |
| Offer For Sale | ₹1,607.00 crore |
| Total IPO Size | ₹1,757.00 crore |
| Face Value | ₹2 |
| Listing On | BSE, NSE |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 24 Aug 2026 |
| IPO Closing Date | 27 Aug 2026 |
| Basis Of Allotment | 28 Aug 2026 |
| Refunds | 31 Aug 2026 |
| Demat Transfer | 31 Aug 2026 |
| IPO Listing Date | 01 Sep 2026 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2024 | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|---|
| Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Total Income | 723.33 | 755.98 | 872.26 |
| Profit After Tax | 100.06 | 96.79 | 109.90 |
| EBITDA | 177.04 | 206.11 | 231.97 |
| NET Worth | 720.68 | 821.15 | 1,158.64 |
| Reserves and Surplus | 709.54 | 810.03 | 1,145.95 |
| Total Borrowing | 247.21 | 540.92 | 387.91 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Symbiotec Pharmalab | 52.00 | 19 | 9.48% | 184.69 |
| Laurus Labs | 109.36 | 16.45 | 16.8% | |
| Cohance Lifesciences | 95.02 | 4.68 | 7% | |
| Divi's Laboratories | 87.8 | 96.75 | 16.5% | 631 |
| Concord Biotech | 61.07 | 24.78 | 14% |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
| Investor Type | Shares Offered |
|---|---|
| Retail Individual Investor (RII) | Not less than 35% of the Net Offer |
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 181.2 |
| Non-Institutional Investor (NII/HNI) | 77.56 |
| Retail Individual Investor (RII) | 13.69 |
| Total | 75.08 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Symbiotec Pharmalab Ltd.385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh – 453331
Website: https://www.symbiotec.com/
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com